Gujarat Themis Biosyn (NSE:GUJTHEM) Cyclically Adjusted PS Ratio: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GUJTHEM Gujarat Themis Biosyn Ltd NSE:GUJTHEM
65 GF Score
Price ₹347.25
GF Value ₹314.19
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Gujarat Themis Biosyn Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gujarat Themis Biosyn  (NSE:GUJTHEM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Gujarat Themis Biosyn Cyclically Adjusted PS Ratio Related Terms


Gujarat Themis Biosyn Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Gujarat Themis Biosyn's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gujarat Themis Biosyn Cyclically Adjusted PS Ratio Chart

Gujarat Themis Biosyn Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.41 13.08 31.46 29.47 20.65

Gujarat Themis Biosyn Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.13 38.48 41.49 20.65 0.00

NSE:GUJTHEM vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Themis Biosyn's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gujarat Themis Biosyn Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gujarat Themis Biosyn's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gujarat Themis Biosyn's Cyclically Adjusted PS Ratio falls into.


NSE:GUJTHEM
65GF Score
Gujarat Themis Biosyn Ltd NSE:GUJTHEM
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gujarat Themis Biosyn Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Gujarat Themis Biosyn's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Gujarat Themis Biosyn's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.036/166.1454*166.1454
=4.036

Current CPI (Jun. 2026) = 166.1454.

Gujarat Themis Biosyn Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.008 105.961 0.013
201612 0.780 105.196 1.232
201703 0.955 105.196 1.508
201706 0.871 107.109 1.351
201709 0.873 109.021 1.330
201712 0.900 109.404 1.367
201803 0.919 109.786 1.391
201806 0.949 111.317 1.416
201809 0.964 115.142 1.391
201812 0.905 115.142 1.306
201903 0.936 118.202 1.316
201906 1.072 120.880 1.473
201909 1.507 123.175 2.033
201912 2.808 126.235 3.696
202003 2.402 124.705 3.200
202006 1.439 127.000 1.883
202009 2.496 130.118 3.187
202012 2.239 130.889 2.842
202103 2.124 131.771 2.678
202106 2.976 134.084 3.688
202109 3.215 135.847 3.932
202112 1.707 138.161 2.053
202203 2.578 138.822 3.085
202206 4.124 142.347 4.813
202209 4.377 144.661 5.027
202212 2.585 145.763 2.946
202303 2.509 146.865 2.838
202306 4.552 150.280 5.033
202309 3.625 151.492 3.976
202312 3.546 152.924 3.853
202403 3.859 153.035 4.190
202406 3.549 155.789 3.785
202409 3.187 157.882 3.354
202412 3.625 158.323 3.804
202503 3.460 157.552 3.649
202506 3.286 159.755 3.417
202509 3.889 162.289 3.981
202512 3.966 163.281 4.036
202603 4.061 164.272 4.107
202606 4.036 166.145 4.036

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Gujarat Themis Biosyn (NSE:GUJTHEM) Overvalued in 2026?

Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued. The current stock price of ₹347.25 is trading 10.5% above its estimated GF Value™ of ₹314.19. GuruFocus considers Gujarat Themis Biosyn to be Modestly Overvalued.

Key valuation signals for NSE:GUJTHEM:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ₹314.19 vs. price of ₹347.25 (10.5% above fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the NSE:GUJTHEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gujarat Themis Biosyn Business Description

Other Exchanges 506879:India
Address S.V Road, Themis House, 11/12 Udyog Nagar, Goregaon (West), Mumbai, MH, IND, 400104
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
65GF Score

Get the complete analysis for NSE:GUJTHEM

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹347.25
Price
₹314.19
GF Value